Chelsea reports net loss in Q3
Operating loss was $8.8m, compared to $7.09m for the comparable period in 2009. For the nine months ended 30 September 2010, Chelsea has posted a net loss of
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
As per the terms of the non-exclusive alliance, Dako and Quintiles will offer integrated drug-diagnostic development services and companion diagnostic products. The first such collaboration will support AstraZeneca